natgillin/translations-raw huggingface dataset:
Pramipexole is commonly associated with somnolence and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (see also section 4.4).
Pramipeksol je često povezan sa somnolencijom te se manje često povezuje s pojavom prekomjerne dnevne somnolencije i epizodama iznenadnog usnivanja (vidjeti također dio 4.4.).
The other ingredients are mannitol, microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate, sodium stearyl fumarate, colloidal silicon dioxide.
Drugi sastojci su manitol, mikrokristalična celuloza, natrijev škroboglikolat, povidon, magnezijev stearat, natrijev stearilfumarat, bezvodni, koloidni silicijev dioksid.
If you experience these side effects, you must not drive or operate machinery.
Ako imate ove nuspojave, ne smijete voziti ili upravljati strojevima.
This will be increased every 4-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
Ova doza se povisuje svakih 4-7 dana prema uputi liječnika, sve dok se simptomi ne stave pod kontrolu (doza održavanja).
In animal studies, pramipexole affected oestrous cycles and reduced female fertility as expected for a dopamine agonist.
U ispitivanjima na životinjama pramipeksol je utjecao na spolne cikluse i smanjenu plodnost ženki kao što se očekivalo za dopaminske agoniste.
During dose escalation in pivotal studies, efficacy was observed starting at a daily dose of 1.1 mg of base (1.5 mg of salt).
Pri povećavanju doze, u pivotalnim studijama, djelotvornost je primijećena počevši od dnevne doze od 1,1 mg baze (1,5 mg soli).
The daily dose can be administered in two divided doses if creatinine clearance is between 20 and 50 ml/min, and as a single daily dose if creatinine clearance is less than 20 ml/min.
Ukupna dnevna doza može se primjenjivati u dvije odvojene doze ako je klirens kreatinina u rasponu od 20 i 50 ml/min te u jednoj dnevnoj dozi ako je klirens kreatinina manji od 20 ml/min.
In a carcinogenicity study, male rats developed Leydig cell hyperplasia and adenomas, explained by the prolactin-inhibiting effect of pramipexole.
U ispitivanju karcinogenosti, muški štakori su razvili hiperplaziju i adenome Leydigovih stanica, što se objašnjava inhibirajućim učinkom pramipeksola na prolaktin.
CGI-I responder rates (much improved, very much improved) were 50.3% (80/159) and 68.5% (111/162) for placebo and pramipexole, respectively (p = 0.001), corresponding to a number needed to treat (NNT) of 6 patients (95%CI: 3.5, 13.4).
Stope odgovora prema CGI-I-u (znatno poboljšanje, veliko poboljšanje) bile su 50,3% (80/159) za placebo i 68,5% (111/162) za pramipeksol (p=0,001), što odgovara broju potrebnom za liječenje (NNT) 6 bolesnika (95%CI: 3,5; 13,4).
• Mania (agitation, feeling elated or over-excited)*
• manija (agitacija, osjećaj ushita ili pretjeranog uzbuđenja)*
After 26 weeks of treatment, there was an adjusted mean reduction in IRLS total score of 13.7 and 11.1 points in the pramipexole and placebo group, respectively, with a statistically significant (p = 0.008) mean treatment difference of -2.6.
Nakon 26 tjedana liječenja, došlo je do prilagođenog prosječnog smanjenja u ukupnom rezultatu IRLS-a od 13,7 točaka u skupini na pramipeksolu i 11,1 u skupini na placebu, sa statistički značajnom (p=0,008) prosječnom razlikom u liječenju od -2,6.
Hallucinations are known as a side effect of treatment with dopamine agonists and levodopa.
Halucinacije su poznata nuspojava liječenja agonistima dopamina i levodopom.
The efficacy of pramipexole (0.0625-0.5 mg/day) with paediatric patients aged 6-17 years with Tourette Disorder was evaluated in a 6-week, double-blind, randomised, placebo-controlled flexible dose study.
Klinička djelotvornost i sigurnost u Touretteovom sindromu Djelotvornost pramipeksola (0,0625-0,5 mg/dan) ocjenjivana je na pedijatrijskim bolesnicima u dobi od 6-17 godina s Touretteovim sindromom tijekom 6 tjedana u dvostruko-slijepom, randomiziranom, placebom kontroliranom, fleksibilnom ispitivanju doza.
Manifestations observed include pathological gambling, compulsive shopping, binge eating, and compulsive sexual behaviour (hypersexuality).
Primijećene manifestacije uključivale su patološku želju za kockanjem, kompulzivnu kupovinu, prejedanje i kompulzivno seksualno ponašanje (hiperseksualnost).
The primary endpoint was change from baseline on the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS).
Primarna ishodna mjera bila je promjena u Ukupnom zbroju tikova (TTS) u tzv. Yale Global Tic Severity Scale (YGTSS) u odnosu na početne vrijednosti.
• Pneumonia (infection of the lungs)*
• upala pluća (infekcija pluća)*
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,923 patients on pramipexole and 1,354 patients on placebo, adverse drug reactions were frequently reported for both groups.
Na temelju analize zbirnih podataka iz placebom kontroliranih ispitivanja koja su obuhvatila 1923 bolesnika na pramipeksolu i 1354 bolesnika na placebu, nuspojave su se često prijavljivale za obje grupe.
High brain tissue concentrations were observed in the rat (approx. 8-fold compared to plasma).
Primijećene su visoke koncentracije u moždanom tkivu štakora (oko 8 puta veće od plazmatskih).
In a 26 week placebo controlled trial, rebound of RLS symptoms (worsening of symptom severity as compared to baseline) was observed in 10% of patients (14 out of 135) after abrupt discontinuation of treatment.
U 26tjednom placebom kontroliranom ispitivanju primijećen je “rebound” fenomen simptoma sindroma nemirnih nogu (pogoršanje težine simptoma u usporedbi s početnim vrijednostima) kod 10% bolesnika (14 od 135) nakon naglog prekida liječenja.
• Excessive daytime sleepiness and suddenly falling asleep
• smetenost • prekomjerna dnevna pospanost i iznenadno usnivanje
Efficacy was observed with 0.088 mg of base (0.125 mg of salt) per day after the first week of treatment.
Djelotvornost je primijećena s dozom od 0,088 mg baze (0,125 mg soli) dnevno nakon prvog tjedna liječenja.
Driving and using machines
Upravljanje vozilima i strojevima Pramipeksol
Infections and infestations pneumonia
Infekcije i infestacije upala pluća
Patients and carers should be made aware that mania and delirium can occur in patients treated with pramipexole.
Bolesnici i njihovi skrbnici moraju biti svjesni mogućnosti pojave manije i delirija kod bolesnika koji se liječe pramipeksolom.
• If you have any further questions, ask your doctor or pharmacist.
- Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
After 12 weeks of treatment the baseline IRLS score improved from 23.5 to 14.1 points for placebo and from 23.4 to 9.4 points for pramipexole (doses combined).
Nakon 12 tjedana liječenja, početne vrijednosti IRLS rezultata poboljšane su sa 23,5 na 14,1 za placebo te s 23,4 na 9,4 za pramipeksol (u kombiniranim dozama).
Pramipexole was not teratogenic in rats and rabbits but was embryotoxic in the rat at maternally toxic doses.
Pramipeksol nije bio teratogen kod štakora i zečeva, ali je bio embriotoksičan u štakora primijenjen u dozama toksičnima za majku.
• treat the symptoms of moderate to severe primary Restless Legs Syndrome in adults.
• liječenju simptoma umjerenog do teškog primarnog sindroma nemirnih nogu.
Adverse events occurring in at least 5% of patients in the pramipexole group and more common in the pramipexole-treated patients than in patients on placebo were: headache (27.9%, placebo 25.0%), somnolence (7.0%, placebo 5.0%), nausea (18.6%, placebo 10.0%), vomiting (11.6%, placebo 0.0%), upper abdominal pain (7.0%, placebo 5.0%), orthostatic hypotension (9.3%, placebo 5.0%), myalgia (9.3%, placebo 5.0%), sleep disorder (7.0%, placebo 0.0%), dyspnoea (7.0%, placebo 0.0%) and upper respiratory tract infection (7.0%, placebo 5.0%).
Nuspojave, koje je imalo najmanje 5% bolesnika u skupini na pramipeksolu i češće u bolesnika liječenih pramipeksolom u odnosu na bolesnike na placebu, bile su: glavobolja (27,9%, placebo 25%), somnolencija (7,0%, placebo 5,0%), mučnina (18,6%, placebo 10,0%), povraćanje (11,6%, placebo 0,0%), bolovi u predjelu gornjeg abdomena (7,0%, placebo 5,0%), ortostatska hipotenzija (9,3%, placebo 5,0%),
• if you are allergic to pramipexole or to any of the other ingredients of this medicine (listed in section 6).
Nemojte uzimati Pramipeksol Teva - ako ste alergični na pramipeksol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Pramipexole Teva contains the active substance pramipexole and belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
Teva sadrži djelatnu tvar pramipeksol i pripada skupini lijekova poznatih kao dopaminski agonisti koji stimuliraju dopaminske receptore u mozgu.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Pramipexole Teva.
Bolesnici i njihovi skrbnici trebaju biti svjesni da se bihevioralni simptomi kod poremaćaja kontrole nagona, uključujući patološku želju za kockanjem, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje, mogu pojaviti kod bolesnika liječenih dopaminskim agonistima, uključujući Pramipeksol Teva.
Approximately 90 % of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
C izlučuje se putem bubrega, dok se manje od 2% nalazi u fecesu.
If you suffer from Parkinson's disease, you may experience the following side effects:
Ako patite od Parkinsonove bolesti, moguće su sljedeće nuspojave: Vrlo često:
Co-administration of antipsychotic medicinal products with pramipexole should be avoided (see section 4.4), e.g. if antagonistic effects can be expected.
Treba izbjegavati istodobnu primjenu antipsihotičnih lijekova i pramipeksola (vidjeti dio 4.4.), npr. ako se očekuju antagnistički učinci.
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including Pramipexole Teva (see section 4.4).
Patološka želja za kockanjem, pojačani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje mogu se pojaviti kod bolesnika liječenih dopaminskim agonistima uključujući pramipeksol. (vidjeti dio 4.4).
The active substance is pramipexole.
Djelatna tvar je pramipeksol.
Rare: • Mania (agitation, feeling elated or over-excited)
Rijetko: - manija (uznemirenost, osjećaj ushita ili pretjeranog uzbuđenja)
Please note:
Napomena:
Dose adjustment in patients with hepatic failure is probably not necessary, as approx. 90 % of absorbed active substance is excreted through the kidneys.
Prilagođavanje doze u bolesnika s oštećenom funkcijom jetre vjerojatno nije potrebno jer se oko 90% apsorbirane djelatne tvari izlučuje putem bubrega.
If necessary, your doctor may increase your tablet dose up to a maximum of 3.3 mg of pramipexole a day.
Bude li potrebno, liječnik može propisati daljnje povećanje doze do najviše 3,3 mg pramipeksola dnevno.
However, your dose may have to be increased even further.
Međutim, liječnik može propisati daljnje povećanje doze.
Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported uncommonly.
U manje čestim slučajevima zabilježena je pojava iznenadnog usnivanja tijekom dana, prilikom obavljanja svakodnevnnih aktivnosti bez prethodnih svjesnih ili upozoravajućih znakova pospanosti.
Pramipexole is bound to plasma proteins to a very low (< 20 %) extent, and little biotransformation is seen in man.
Pramipeksol se u vrlo maloj mjeri veže na proteine plazme (<20%) te se slabo biotransformira u ljudi.
Investigations weight decrease including decreased appetite weight increase
Pretrage smanjenje težine uključujući smanjeni apetit povećanje težine
• You may experience vomiting, restlessness, or any of the side effects as described in chapter 4
• Mogli biste imati nuspojave kao što je povraćanje, nemir ili bilo koju drugu nuspojavu opisanu u dijelu 4 „Moguće nuspojave“.
6.5 Nature and contents of container Aluminium/Aluminium Blister
Aluminij/aluminij blister
If you forget to take Pramipexole Teva
Ako ste zaboravili uzeti Pramipeksol Teva
Symptoms suggestive of neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see section 4.2).
Simptomi koji upućuju na maligni neuroleptički sindrom zabilježeni su uz nagli prekid dopaminergičke terapije (vidjeti dio 4.2.).
Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).
Pramipeksol Teva je indiciran za simptomatsko liječenje umjerenog do teškog idiopatskog sindroma nemirnih nogu u odraslih pri dozama do 0,54 mg baze (0,75 mg soli) (vidjeti dio 4.2).
• Delusion*
• zablude (deluzije)*
Sudden onset of sleep and somnolence
Epizode iznenadnog usnivanja i somnolencija
The European Medicines Agency has deferred the obligation to submit the results of studies with pramipexole in one or more subsets of the paediatric population in Restless Legs Syndrome (see section 4.2 for information on paediatric use).
Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja pramipeksola u jednoj ili više podskupina pedijatrijske populacije sa sindromom nemirnih nogu (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses (see section 5.3).
Pramipeksol se nije pokazao teratogenim na štakorima i zečevima, ali je bio embriotoksičan na štakorima pri dozama toksičnima za majku (vidjeti dio 5.3).
If dystonia occurs, the dopaminergic medication regimen should be reviewed and an adjustment in the dose of pramipexole considered.
U slučaju pojave distonije potrebno je preispitati režim davanja dopaminergičkih lijekova i razmotriti prilagodbu doze pramipeksola.
For both primary endpoints statistically significant differences have been observed for the pramipexole dose groups 0.25 mg, 0.5 mg and 0.75 mg pramipexole salt in comparison to placebo.
Za obje primarne ishodne mjere primijećene su statistički značajne razlike za skupine na dozama pramipeksola u obliku soli od 0,25 mg, 0,5 mg, 0,75 mg u usporedbi s placebom.
The expected adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, agitation and hypotension.
Očekivane nuspojave su one povezane s farmakodinamičkim profilom agonista dopamina, uključujući mučninu, povraćanje, hiperkineziju, halucinacije, agitaciju i hipotenziju.
747 70 Opava-Komarov Czech Republic
Ostravska 29, c.p. 305 747 70 Opava-Komarov Češka Republika
• Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)).
- Distonija (nemogućnost držanja tijela i vrata ravno i uspravno (aksijalna distonija)).
4.1 Therapeutic indications
4.1 Terapijske indikacije Pramipeksol
You should have regular eye examinations during treatment with Pramipexole Teva.
Trebali biste redovito obavljati pregled očiju tijekom liječenja Pramipeksolom
Pramipexole Teva can be taken with or without food.
Pramipeksol Teva se može uzimati s hranom ili bez nje.
(≥1/1,000 to <1/100)
Manje često (≥1/1000 i <1/100)
To discontinue treatment in patients with Parkinson's disease, pramipexole should be tapered off (see section 4.2).
Da bi se prekinulo liječenje u bolesnika s Parkinsonovom bolešću, pramipeksol je potrebno postupno ukidati (vidjeti dio 4.2).
No difference was observed for pramipexole as compared to placebo for either the primary endpoint or for any of the secondary efficacy endpoints including YGTSS total score, Patient Global Impression of Improvement (PGI-I), Clinical Global Impression of Improvement (CGI-I), or Clinical Global Impressions of Severity of Illness (CGI-S).
Nije primijećena razlika za pramipeksol u usporedbi s placebom, bilo za primarnu ishodnu mjeru ili za neku od sekundarnih ishodnih mjera djelotvornosti, uključujući ukupni rezultat YGTSS-a, bolesnikov opći dojam poboljšanja (engl.
Pramipexole Teva should not be used in children or adolescents with Tourette Disorder because of a negative benefit-risk balance for this disorder (see section 5.1).
Teva se ne smije primjenjivati u djece ili adolescenata s Tourettovim sindromom zbog negativnog omjera koristi i rizika za ovaj poremećaj (vidjeti dio 5.1).
Pharmachemie B.V. Swensweg 5, Postbus 552, 2003 RN Haarlem The Netherlands
Postbus 552, 2003 RN Haarlem
If renal function declines during maintenance therapy, the Pramipexole Teva daily dose should be reduced by the same percentage as the decline in creatinine clearance, i.e. if creatinine clearance declines by 30 %, then the Pramipexole Teva daily dose should be reduced by 30 %.
Teva je potrebno sniziti u istom postotku za koji se smanjio klirens kreatinina, tj. ako se klirens smanjio za 30%, tada je potrebno sniziti ukupnu dnevnu dozu Pramipeksol Teva za 30%.
• Hallucinations (seeing, hearing or feeling things that are not there)
• halucinacije (vidjeti, čuti ili osjećati stvari koje nisu prisutne)
Patients with a creatinine clearance above 50 ml/min require no reduction in daily dose or dosing frequency.
U bolesnika s klirensom kreatinina većim od 50 ml/min nije potrebno smanjivati dnevnu dozu ili učestalost doziranja.
• procainamide (to treat irregular heart beat).
• prokainamid (za liječenje nepravilnog kucanja srca)
There is no established antidote for overdose of a dopamine agonist.
Nije poznat specifični antidot za predoziranje agonistom dopamina.
(≥1/100 to
Često (≥1/100 i
UAB Sicor Biotech Eesti filiaal Tel: +372 6610801
UAB Sicor Biotech filiāle Latvija Tel: +371 67323666
Treatment discontinuation
Prekid liječenja
The mechanism of action of pramipexole as treatment for Restless Legs Syndrome is unknown.
Mehanizam djelovanja pramipeksola u liječenju sindroma nemirnih nogu nije poznat.
90 tablets
Tablete 90 tableta
Number of tablets
Broj tableta
Patients with a creatinine clearance above 20 ml/min require no reduction in daily dose.
U bolesnika s klirensom kreatinina iznad 20 ml/min nema potrebe za snižavanjem dnevne doze.
In clinical studies and post-marketing experience cardiac failure has been reported in patients with pramipexole.
U kliničkim ispitivanjima i u postmarketinškom praćenju prijavljeno je zatajenje srca kod bolesnika koji su uzimali pramipeksol.
mania
manija
Pack sizes: 90 tablets.
Veličina pakiranja: 90 tableta.
You can take Pramipexole Teva with or without food.
Pramipeksol Teva možete uzimati s hranom ili bez hrane.
30 tablets 50 x 1 tablets 100 tablets 30 x 1 tablets 100 x 1 tablets
30 tableta 50 x 1 tableta 100 tableta 30 x 1 tableta 100 x 1 tableta
How to take Pramipexole Teva
Kako uzimati Pramipeksol Teva
However, the potential influence of hepatic insufficiency on Pramipexole Teva pharmacokinetics has not been investigated.
Međutim, potrebno je znati da potencijalni utjecaj insuficijencije jetre na farmakokinetiku Pramipeksola
The excretion of pramipexole into breast milk has not been studied in women.
Izlučivanje pramipeksola u majčinom mlijeku kod žena nije ispitivano.
Infections and infestations pneumonia1
Infekcije i infestacije upala pluća1
6.6 Special precautions for disposal
6.6. Posebne mjere za zbrinjavanje
The elimination of pramipexole is dependent on renal function.
Eliminacija pramipeksola ovisi o bubrežnoj funkciji.
For patients requiring additional symptomatic relief, the dose may be increased every 4-7 days to a maximum of 0.54 mg of base (0.75 mg of salt) per day (as shown in the table below).
Za bolesnike kojima je potrebno dodatno ublažavanje simptoma doza se može povećavati svakih 4-7 dana, maksimalno do 0,54 mg baze (0,75 mg soli) dnevno, kao što je prikazano u donjoj tablici.
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.5, 4.7 and section 4.8).
Zbog mogućih dodatnih učinaka, oprez je potreban u bolesnika koji uzimaju sedative ili alkohol u kombinaciji s pramipeksolom (vidjeti dijelove 4.5, 4.7 i 4.8).
If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with Pramipexole Teva.
Ako uzimate levodopu, preporučuje se da se doza levodope smanji kad započnete uzimati Pramipeksol
Concomitant administration with food did not reduce the extent of pramipexole absorption, but the rate of absorption was reduced.
Primjena pramipeksola istodobno s hranom nije smanjila ukupnu apsorpciju pramipeksola, ali ju je usporila.
Pramipexole Teva is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy.
Teva se ne preporučuje u djece i adolescenata u dobi do 18 godina zbog nedostatnih podataka o sigurnosti i djelotvornosti.
Symptoms include apathy, anxiety, depression, fatigue, sweating and pain which may be severe.
Simptomi uključuju apatiju, anksioznost, depresiju, umor, znojenje i bol koja može biti jaka.
Psychiatric disorders insomnia abnormal dreams restlessness confusion hallucinations libido disorder delusion1 hyperphagia1 paranoia1 mania1 delirium1
Psihijatrijski poremećaji nesanica abnormalni snovi nemir smetenost halucinacije poremećaj libida sumanutost1 hiperfagija1 paranoja1 manija1 delirij1
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.4, 4.7 and 4.8).
Zbog mogućih dodatnih učinaka oprez je potreban u bolesnika koji uzimaju sedative ili alkohol u kombinaciji s pramipeksolom (vidjeti dijelove 4.4, 4.7 i 4.8).
A more frequent adverse drug reaction in combination with levodopa was dyskinesia.
Češća nuspojava u kombinaciji s levodopom bila je diskinezija.
Vascular disorders hypotension
Krvožilni poremećaji hipotenzija
The overall incidence of hallucinations and somnolence was generally higher in the escalation phase with the pramipexole group.
Ukupna incidencija halucinacija i somnolencije bila je općenito veća tijekom perioda povećanja doze u grupi bolesnika liječenih pramipeksolom.
2nd week
2. tjedan
Parkinson's disease, most common adverse reactions The most commonly (≥ 5 %) reported adverse drug reactions in patients with Parkinson's disease more frequent with pramipexole treatment than with placebo were nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache and fatigue.
Najčešće (≥5%) prijavljene nuspojave u bolesnika s Parkinsonovom bolešću, češće kod liječenja pramipeksolom nego placebom, bile su mučnina, diskinezija, hipotenzija, omaglica, somnolencija, nesanica, konstipacija, halucinacija, glavobolja i umor.
• zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system)
• zidovudin (koji se može koristiti za liječenje Sindroma stečene imunodeficijencije (SIDA),
When Pramipexole Teva is given in combination with levodopa, it is recommended that the dose of levodopa is reduced and the dose of other anti-parkinsonian medicinal products is kept constant while increasing the dose of Pramipexole Teva.
Teva primjenjuje u kombinaciji s levodopom, preporučuje se sniziti dozu levodope i ne mijenjati doze ostalih antiparkinsonika dok se povisuje doza Pramipeksol Teva.
Dopamine agonist withdrawal syndrome
Sindrom ustezanja od agonista dopamina
Pack sizes: 30, 30 x 1, 50 x 1, 100 x 1 and 100 tablets Polyethylene tablet container with CRC polypropylene cap.
Veličina pakiranja: 30, 30 x 1, 50 x 1, 100 x 1 i 100 tableta Polietilenski spremnik za tablete s polipropilenskim sigurnosnim zatvaračem za djecu.
A lower maintenance dose of three Pramipexole Teva 0.088 mg tablets a day is also possible.
Moguća je također i niža doza održavanja od tri Pramipeksol Teva 0,088 mg tablete dnevno.